code General Sarepta Therapeutics to Participate in Upcoming Investor Conferences Read more about Sarepta Therapeutics to Participate in Upcoming Investor Conferences Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference Read more about Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference Sarepta Therapeutics to Announce First Quarter 2026 Financial Results Read more about Sarepta Therapeutics to Announce First Quarter 2026 Financial Results Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 Read more about Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 Read more about Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® Read more about Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne Read more about Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program Read more about Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress Read more about Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress Pagination Page 1 Next page ›› Subscribe to General Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Sarepta Therapeutics to Participate in Upcoming Investor Conferences Read more about Sarepta Therapeutics to Participate in Upcoming Investor Conferences
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference Read more about Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results Read more about Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 Read more about Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 Read more about Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® Read more about Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne Read more about Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program Read more about Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress Read more about Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
